Sodium thiosulfate - Decibel Therapeutics
Alternative Names: DB-020Latest Information Update: 28 Dec 2024
At a glance
- Originator Decibel Therapeutics
- Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates; Vasodilators
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sensorineural hearing loss
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Sensorineural hearing loss(Prevention) in Australia (Intratympanic, Injection)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Sensorineural hearing loss(Prevention) in USA (Intratympanic, Injection)
- 31 May 2024 Updated adverse events data from a phase I trial in Sensorineural hearing loss presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)